Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bruker BioSciences Corporation to Release Second Quarter 2007 Financial Results on July 31, 2007.


BILLERICA, Mass. -- Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use.  (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:BRKR BRKR Breaker ) plans to release its second quarter 2007 financial results on Tuesday, July 31, 2007 before the market opens. Bruker BioSciences will then host an operator-assisted earnings conference call that morning at 9 a.m. Eastern Time. To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days.

Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada. Investors should refer to the Bruker BioSciences Call. A telephone replay of the conference call will be available two hours after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 72671589.

ABOUT BRUKER BIOSCIENCES (NASDAQ:BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics Inc. The Company is a leading developer and provider of advanced X-ray tools used primarily in life science and materials research, as well as of X-ray and OES elemental analysis instrumentation used primarily in industrial applications. It is also a leading developer and provider of innovative life science tools based on mass spectrometry mass spectrometry
 or mass spectroscopy

Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields.
 and develops and provides a broad range of field analytical systems for chemical, biological, radiological and nuclear detection. In addition, it is a leading developer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology.

For more information, please visit www.bruker-biosciences.com

BRUKER BIOSCIENCES CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future, technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending capital spending

Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years.
 and government funding policies, FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.


Form 10-K

See 10-K.
 for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Date:Jul 25, 2007
Words:478
Previous Article:BullMarket.com Offers Investment Opinions on Local.com, Jamba, Quest Diagnostics, American Express, and Western Union.
Next Article:Atos Origin Signs Contract with Catalent Pharma Solutions for Outsourcing of IT Infrastructure.



Related Articles
Teddy's dictum.
Porter's time well-spent.
No kidding: These tots can shop.
FOR THE RECORD.
Mouse method turns skin cells to stem cells.
Business Objects Reports Q2 Fiscal 2007 Results.
Insmed Announces Second Quarter and First Half Earnings Release Date and Conference Call.
Convergys Corporation Reports Second Quarter Results and Updates Guidance.
Omni Financial Services, Inc. Reports Record Second Quarter Earnings of $1.71Million, Growth of 21.3% and Declares Dividend.
Honda Announces Consolidated Financial Summary for the Fiscal 1st Quarter Ended June 30, 2007; All-time Q1 Record for Net Sales, Operating Income,...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles